user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 413464 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.

Ariad Pharmaceuticals Shares Climbing Higher, Up 4.8%

Published on Wed, 01/02/2013 - 11:28
By Robert Cotter

Ariad Pharmaceuticals (NASDAQ:ARIA) is a company whose shares are active, trading 4.8% higher to $20.10. The S&P is currently trading 1.8% higher to 1,452 and the Dow Jones Industrial Average is trading 1.8% higher to 13,339.

Ariad Pharmaceuticals share prices have moved between a 52-week high of $25.40 and a 52-week low of $12.26 and are now trading 64% above that low price at $20.10 per share. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.7% while the 200-day MA has risen 0.5%.

Ariad Pharmaceuticals has overhead space with shares priced $20.10, or 30.4% below the average consensus analyst price target of $28.88. The stock should find resistance at its 50-day moving average (MA) of $21.57, as well as support at its 200-day MA of $19.27.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Analyst Rating Flashback: Nanometrics Do...

One week ago Nanometrics (NASDAQ:NANO) was downgraded from Buy to Hold at Canaccord Gen ...

Analyst Rating In Review: Sigma-Aldrich ...

Keybanc downgraded Sigma-Aldrich (NASDAQ:SIAL) from Buy to Hold a week ago. The shares ...

Dick's Sporting Goods Gives Way to the A...

A week ago, William Blair downgraded Dick's Sporting Goods from Outperform to Market Pe ...

SunTrust Made the Right Call, ShoreTel 6...

ShoreTel was upgraded from Neutral to Buy by SunTrust one week ago. ShoreTel shares ar ...

Clorox In Retrospect: Shares Down 1.0% S...

A week ago, Citigroup downgraded Clorox from Buy to Neutral. Clorox shares are selling ...

Analyst Rating In Review: Clorox Sold Of...

A week ago, B. Riley downgraded Clorox from Neutral to Sell. The shares closed at $96. ...

Bed Bath & Beyond Defies the Rating: Up ...

A week ago, William Blair downgraded Bed Bath & Beyond from Outperform to Market Perfor ...

Wells Fargo Made the Right Call, Fluor 1...

Wells Fargo downgraded Fluor (NYSE:FLR) from Outperform to Market Perform a week ago. ...